BLCO Stock Forecast & Price Target

Bausch & Lomb is attractive fundamentally because it is shifting toward faster-growing, higher-margin businesses in dry eye, premium contact lenses, and premium intraocular lenses, while still benefiting from a broad portfolio of over 100 eye-care products. Its pharmaceuticals franchise is supported by MIEBO’s differentiated speed of relief and XIIDRA’s stabilizing gross-to-net, with management expecting dry-eye demand to broaden as untreated and under-treated patients enter the funnel. On the surgical and vision care sides, strong adoption of premium daily SiHy lenses and recovering enVista Envy momentum, along with a 2027 premium IOL launch, support EBITDA improvement, margin expansion, and a case for the shares to re-rate versus peers.

Bausch & Lomb is facing multiple fundamental risks that could pressure both revenue growth and margins, including MIEBO sales potentially missing the FY2026 guide, weaker consumer demand in its OTC business, and contact lens sales that may not keep pace with expectations. Its Surgical segment has been supported by above-market gains in premium IOLs, but any slowdown would likely hurt mix and compress margins, while a stalled bioactive contact lens pipeline could undermine expected growth and margin expansion beginning at the end of the decade. With more than 100 products and leadership across vision care, surgical, and ophthalmic pharmaceuticals, the company still has breadth, but its outlook is vulnerable if key growth drivers underdeliver.